Association of CYP2C19 Polymorphism With Proton Pump Inhibitors Effectiveness and With Fractures in Real‐Life: Retrospective Cohort Study

Symptom refractoriness of patients treated with proton pump inhibitors (PPIs) might be explained by polymorphism in CYP2C19. This is a retrospective cohort study in which we used the computerized database of Clalit Health Services to compose a cohort from cancer case‐control studies’ participants th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gronich, Naomi, lavi, Idit, Lejbkowicz, Flavio, Pinchev, Mila, Rennert, Gad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311419/
https://www.ncbi.nlm.nih.gov/pubmed/35124810
http://dx.doi.org/10.1002/cpt.2552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311419/
https://www.ncbi.nlm.nih.gov/pubmed/35124810
http://dx.doi.org/10.1002/cpt.2552

Ejemplares similares